Incyte causes stir with experimental drug data

Incyte made a stir at JP Morgan with positive early-stage results for its experimental drugs aimed at rheumatoid arthritis and diabetes. Its shares jumped about 25 percent on the news. Chief Executive Dr. Paul Friedman said early data from INCB18424 appear to show "at least equal, and possibly superior," results compared to other biologics, adding that the drug was well tolerated.

- read the release

Suggested Articles

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.

Since Takeda bought out Shire, it’s lost a number of high-ranking research execs from the Irish rare disease biotech; it’s also losing one of its own.